Human papillomavirus reporting: Minimizing patient and laboratory risk

Archives of Pathology and Laboratory Medicine

Volumn 127, Issue 8, 2003, Pages 973-977

  Austin, R Marshall ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b Department of Cytopathology and Gynecologic Pathology Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADENOCARCINOMA; CANCER SCREENING; CLINICAL TRIAL; CONFERENCE PAPER; DIAGNOSTIC VALUE; DNA DETERMINATION; HUMAN; LABORATORY TEST; PAPANICOLAOU TEST; PUBLIC HEALTH SERVICE; RISK MANAGEMENT; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VALIDATION PROCESS; VIRUS DETECTION; WART VIRUS; CLASSIFICATION; CYTODIAGNOSIS; FEMALE; HOSPITAL LABORATORY; INFORMATION SYSTEM; ISOLATION AND PURIFICATION; LEGAL ASPECT; PAPILLOMA VIRUS; PATHOLOGY; PATIENT SATISFACTION; REVIEW; STANDARD; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

CYTODIAGNOSIS; FEMALE; HUMANS; INFORMATION SYSTEMS; LABORATORIES, HOSPITAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATIENT SATISFACTION; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 0042674408     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Carmichael DE. The Pap Smear: Life of George N. Papanicolaou. Springfield, III: Charles Thomas Publisher; 1973.
2. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941;42:193-206.
3. Erickson CC, Everett BE Jr, Graves LM, et al. Population screening for uterine cancer by vaginal cytology: preliminary results of first examination of 108,000 women and second testing of 33,000 women. JAMA. 1956;62:167-173.
4. Christopherson WM, Parker JE, Drye JC. Control of cervical cancer: preliminary report on a community program. JAMA. 1962;182:179-182.
5. Bogdanich, W. Lax laboratories: the Pap test misses much cervical cancer through labs' errors. Wall Street Journal. November 2, 1987.
6. Triol JH, Russell C, Ashton PA. Health Care Financing Administration/American Society for Cytotechnology inspections: government assessment of cytology laboratory practice under regulations of the Clinical Laboratory Improvement Amendments of 1988. Arch Pathol Lab Med. 1997;121:264-266.
7. Austin RM. College of American Pathologists Conference XXX on Quality and Liability Issues With the Papanicolaou Smear: introduction. Arch Pathol Lab Med. 1997;121:227-228.
8. Perey R. Cervical cancer and the misdiagnosed Pap Smear. Seattle, Wash: Law Office of Ron Perey Trial Lawyers; March 1997.
9. Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion. Cancer prevention and control: cervical cancer and Pap smear information. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/cancer/nbccedp/info-cc.htm. Accessed August 28, 2002.
10. Van den Akker-van Marle ME, van Ballegooijen MV, van Oartmarssen GJ, Boer R, Habbema JDF. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J Natl Cancer Inst. 2002;94:193-204.
11. Austin RM. Who should decide how effective cervical cancer screening should be? J Reprod Med. 1999;44:317-320.
12. Raslavicus P. Crisis in liability insurance coverage. CAP Today. August 2002:11.
13. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance. J Natl Cancer Inst. 2001;93:293-299.
14. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the Management of Women With Cervical Abnormalities. JAMA. 2002;287:2120-2129.
15. Stoler MH. New Bethesda terminology and evidence-based management guidelines for cervical cytology findings. JAMA. 2002;287:2140-2141.
16. Bierig JR. Liability and payment issues in the selection of pathology assays. Arch Pathol Lab Med. 2002;126:652-657.
17. Kinney WK, Manos MM, Hurley LB, et al. Where's the high risk neoplasia? The importance of the minimally abnormal Papanicolaou diagnosis. Obstet Gynecol. 1998;91:973-976.
18. Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province cervical screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. 2001;83:439-444.
19. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
20. Quiddus MR, Sung Q, Steinhoff MM, et al. Atypical squamous metaplastic cells: reproducibility, outcome, and diagnostic features on Thin Prep Pap test. Cancer. 2001;93:16-22.
21. Jones BA, Novis DA. Follow-up of abnormal gynecologic cytology: a College of American Pathologists Q-Probes study of 16 132 cases from 306 laboratories. Arch Pathol Lab Med. 2000;124:665-671.
22. Evidence Report/Technology Assessment Number 5: Evaluation of Cervical Cytology. Rockville, Md: US Dept of Health and Human Services, Agency for Health Care Policy and Research; 1999. AHCPR Publication 99-E010.
23. Wilbur DC, Prey MU, Miller WM, Pawlick GF, Colgan TJ. The AutoPap system for primary screening in cervical cytology. Acta Cytol. 1998;42:214-220.
24. Renshaw AA. Estimating the percentage of Papanicolaou smears that can be reproducibly identified. Cancer Cytopathol. 2001;93:241-245.
25. Schiffman M. Epidemiology. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. 5th ed. New York, NY: Springer-Verlag; 2002:1301-1318.
26. Meiijer CJLM, Rozendaal L, van der Linden JC, Helmerhorst Th JM, Voorhoorst FJ, Walboomers JMM. Human papillomavirus testing for primary screening. In: Franco E, Monsonego J, eds. New Developments in Cervical Screening and Prevention. Malden, Mass: Blackwell Science; 1997.
27. Birdsong GG. FDA panel reviews proposal for use of HPV testing in conjunction with Pap tests as a primary screening modality in women 30 years and older. ASC Bulletin. 2002;39:60-67.
28. Rozendaal L, Walboomer JMM, van der Linden JC, et al. PCR-based high risk HPV test in cervical cancer screening gives objective high risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer. 1996;68: 766-769.
29. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous lesions. J Natl Cancer Inst. 1999;91:954-960.
30. Hutchinson ML, Zahniser DJ, Shermanm ME, et al. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer Cytopathol. 1999;87:48-55.
31. Baldauf JJ, Dreyfus M, Lehmann M, Ritter J, Phillipe E. Cervical cancer screening with cervicography and cytology. Eur J Obstet Gynecol Reprod Biol. 1995;58:33-39.
32. Davison JM, Marty JJ. Detecting premalignant cervical lesions: contributions of screening colposcopy to cytology. J Reprod Med. 1994;39:388-392.
33. Solomon D, Schiffman M, Tarone R. ASCUS LSIL Triage Study (ALTS) conclusions reaffirmed: response to a November 2001 commentary. Obstet Gynecol. 2001;99:671-674.
34. Jain S, Tseng CJ, Horng SG, Soong YK, Pao CC. Negative predictive value of human papillomavirus test following conization of the cervix uteri. Gynecol Oncol. 2001; 82: 177-180.
35. Lin CT, Tesng CJ, Lai CH, et al. Value of human papillomavirus deoxyribonucleicacid testing after conization in the prediction of residual disease in the subsequent hysterectomy specimen. Am J Obstet Gynecol. 2001;184:940-945.
36. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the united states: a 24 year population-based study. Gynecol Oncol. 2000;78:97-105.
37. Janerich DT, Hadjmichael O, Schwartz PE, Lowell DM, Meigs JW, Merino M. The screening histories of women with invasive cervical cancer, Connecticut. Am J Publ Health. 1995;85:791-794.
38. Mitchell H, Medley G, Gordon I, Giles G. Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong benefit. Br J Cancer. 1995;81:159-166.
39. Nieminen P, Kallio M, Hakama M. The effect of mass screening on incidence and mortality of squamous and adenocarcinoma of the cervix uteri. Obstet Gynecol. 1995;85:1017-1021.
40. Raab SS, Snider TE, Potts SA, et al. Atypical glandular cells of undetermined significance: accuracy and interobserver variability using select cytologic criteria. Am J Clin Pathol. 1997;107:299-307.
41. Ronnett BM, Manos MM, Ransley JE, Fetterman BJ, Kinney WJ, Hurley LB. Atypical glandular cells of undetermined significance: cytopathologic features, histopathologic results, and human papillomavirus DNA detection. Hum Pathol. 1999;30:816-825.
42. Pirog EC, Kleter B, Olgac S, et al. Prevalence of human papillomavirus DNA in different histologic subtypes of cervical adenocarcinoma. Am J Pathol. 2000;157:1055-1062.
43. Smith-McCune K, Mancuso V, Constant T. Management of women with atypical Papanicolaou tests of undetermined significance by board-certified gynecologists: discrepancies with published guidelines. Am J Obstet Gynecol. 2001; 185:551-557.
44. Brown AD, Raab SS, Suba EJ, Wright RG. Cost-effectiveness studies on cervical cancer. Acta Cytol. 2001;45:509-514.
45. Montz FJ, Farber FJ, Bristow RE, Cornelison T. Impact of increasing Papanicolaou test sensitivity and compliance: a new modelled cost and outcomes analysis. Obstet Gynecol. 2001;97:781-788.